Zenas BioPharma (NASDAQ: ZBIO) furnishes Q2 2025 results press release

Rhea-AI Filing Summary

Zenas BioPharma, Inc. filed a current report to note that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release, dated August 12, 2025, is furnished as Exhibit 99.1.

The company’s common stock, par value $0.0001 per share, trades on The Nasdaq Global Select Market under the symbol ZBIO. The information in this report and Exhibit 99.1 is furnished rather than filed under the Exchange Act, which limits how it is treated for certain liability and incorporation-by-reference purposes.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001953926 0001953926 2025-08-12 2025-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

ZENAS BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-42270		93-2749244
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
852 Winter Street, Suite 250 Waltham, MA				02451
(Address of principal executive offices)				(Zip Code)

(Registrant’s telephone number, including area code): (857) 271-2954

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ZBIO		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Zenas BioPharma, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by the Company on August 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ZENAS BIOPHARMA, INC.
	By:	/s/ Jennifer Fox
		Name:	Jennifer Fox
		Title:	Chief Business Officer and Chief Financial Officer

Date: August 12, 2025

FAQ

What did Zenas BioPharma (ZBIO) disclose in this Form 8-K?

Zenas BioPharma disclosed that it issued a press release announcing its financial results for the quarter ended June 30, 2025, which is furnished as Exhibit 99.1.

Which period’s results does Zenas BioPharma’s press release cover?

The press release announced by Zenas BioPharma covers financial results for the quarter ended June 30, 2025.

How is the information in this Zenas BioPharma 8-K treated under the Exchange Act?

The company states that the information in this report and Exhibit 99.1 is furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities or automatically incorporated into other filings.

What exhibit did Zenas BioPharma attach with this Form 8-K?

Zenas BioPharma attached Exhibit 99.1, which is the press release issued on August 12, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

On which exchange does Zenas BioPharma (ZBIO) trade and what is its listed security?

Zenas BioPharma’s common stock, par value $0.0001 per share, trades on The Nasdaq Global Select Market under the trading symbol ZBIO.

Who signed this Zenas BioPharma Form 8-K?

The Form 8-K was signed on behalf of Zenas BioPharma, Inc. by Jennifer Fox, the company’s Chief Business Officer and Chief Financial Officer, dated August 12, 2025.